期刊文献+

基因工程药物中包含体复性的研究进展

下载PDF
导出
摘要 以大肠杆菌作为表达系统生产基因工程药物时,药物蛋白通常会形成无活性的蛋白聚体即包含体,它们的一级结构即氨基酸序列是正确的,但空间结构错误,没有生物学活性。需要一个复性过程才能得到生物活性蛋白。近年来,发展了许多策略来从包含体中复性重组蛋白,包括利用层析复性以及用一些低分子量的添加剂等来提高活性蛋白的产率。
作者 张林忠
出处 《海峡药学》 2006年第3期11-13,共3页 Strait Pharmaceutical Journal
  • 相关文献

参考文献15

  • 1Walsh,G,Biopharmaceutical benchmarks[J].Nat Biotechnol 2003,21:865~870
  • 2Isumoto,K,Ejima,D,Kumagai,I,Practical considerations in refolding proteins from inclusion bodies[J].Protein Expr Purif.2003,28:1~8
  • 3Derman A I,Prinz W,Belin D et al.Mutations that allow disulfide bond formation in the cytosol of Escherichia coli[J].Sciene,1993,262:1744~1747
  • 4Lili H,Schwarz E,Rudolph R.Advances in refolding of proteins produced in E.coli[J].Curr Opin Biotechnol,1998,9:497~501
  • 5Patra A K,Mukhopadhyay et al.Optimization of inclusion body solubilization and renaturation of recombinant human growth hormong from Escherichia coli[J].Protein Expr Purif,2000,18:338~393
  • 6Kiefer H,Maier K,Refolding of G-protein-coupled receptors from inclusion bodies produced in Escherichia coli[J].Biochem SocTrans,1999,27(6):903~911
  • 7Panda,A K,Bioprocessing of the therapeutic proteins from the inclusion bodies of Escherichia coli[J].Adv Biochem Eng Biotechnol,2003,85:43~93
  • 8Hevehan D L,Clark E D B.Oxidative renaturation of lysozyme at high concentration[J].Biotechnol Bioeng.
  • 9Xie Y,Wetlaufer D B.Control of aggregation in protein folding:the temperature-leap tactic[J].Protein Sci,1996,5:517~523.
  • 10焦建伟,俞梅敏,茹炳根.凝胶色谱柱复性在低分子量尿激酶原突变体(DscuPA-32K)中的应用[J].生物工程学报,2001,17(3):300-303. 被引量:4

二级参考文献9

  • 1SONG G (宋刚),YU M (于敏),SONG H Y (宋后燕) et al. R ati onal Design, Over-expression and Characterization of a Navel Staphylokinase wit h Lower Tendency of Polymerization. Engineering Science(中国工程科学),2000 ,2(11):68
  • 2David R Phillips, Israel F Charo, Laurence A Fitzgerald et al. The platelet membrane glycoproteinⅡb-Ⅲa complex. Blood, 1998, 71(4):1
  • 3Huang T F, Shen J R, Liu C S et al. Triflavin. an antiplatel et Arg-Gly-As p-containing peptide, is a specific antagonist of platelet membrane glycoprotei nⅡb/Ⅲa complex. J Biochem(Tokyo), 1991,109:328
  • 4Walda B.van Zyl, Gert H J Pretorius, Harry F Kotze et al. Pr oduction of a r ecombinant antithrombotic and fibrinolytic protein, PLATSak, in Escherichia co li. Thrombosis reserch, 1997, 88: 419~426
  • 5Batas B,Chaudhuri J B. Protein refolding at high concentration u sing size-exclusion chromatography. Biotechnol Bioengin, 1996,50:16~23
  • 6Zhan C H, Liang D C, Song H Y et al. Crystallyzation and pre liminary X-ray diffraction studies of recombinant staphylokinase. Acta Cryst, 1996, 52:564~565
  • 7Rabins A, De Bondt H L, De Ranter C. Three-dimensional-struct ure of staphylo kinase, a plasmingen activator with thrapeutical potential. Nat Struct Biol, 1997,4:357~360
  • 8Ohlenschlager D, Ramachandran R, Brown LR. Nuclear magnetic res onance solut ion structure of the plasminogen-activator protein staphylokinase. Biochemist ry, 1998,37:10635~10642
  • 9龙建银,王会信.重组蛋白的体外再折叠[J].生理科学进展,1998,29(2):103-108. 被引量:4

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部